Dr Shabbir Moochhala
Consultant Nephrologist
Digestive Health
Sub-specialties: Renal Medicine, Chronic Kidney Disease, Hypertension, Electrolyte Disorders, Rare Kidney Diseases, Kidney Stone Prevention, Nephrology, Kidney Disease.
Overview
Dr Shabbir Moochhala is a Consultant Nephrologist at OneWelbeck. He is very experienced in all aspects of kidney disease, including chronic kidney disease and hypertension, and is also an accredited general physician. Dr Moochhala lectures internationally on rare kidney diseases and runs research trials at the Royal Free Hospital.
About Dr Shabbir Moochhala
Areas of Expertise
Dr Shabbir Moochhala treats various conditions including the following:
- Renal Medicine
- Chronic kidney disease
- Hypertension
- Electrolyte disorders
- Rare kidney diseases
- Kidney stone prevention
- Nephrology
- Kidney disease
Some of the treatments and procedures Dr Moochhalaoffers are:
- Renal biopsy
Additional Information
Awards
- National lead for NHS Rare Disease Collaborative Network in hyperoxaluriaChair of OxalEurope
Memberships
- Royal College of Physicians of Edinburgh
- UK Kidney Association
- European Renal Association
- European Association of Urology (Section of Urolithiasis)
- OxalEurope
- Oxalosis and Hyperoxaluria Foundation
Research Highlights
Dr Shabbir Moochhala
Key Publishications
- Wong K, Pitcher D, Braddon F, Downward L, Steenkamp R, Annear N, Barratt J, Bingham C, Chrysochou C, Coward RJ, Game D, Griffin S, Hall M, Johnson S, Kanigicherla D, Karet Frankl F, Kavanagh D, Kerecuk L, Maher ER, Moochhala S, Pinney J, Sayer JA, Simms R, Sinha S, Srivastava S, Tam FWK, Turner AN, Walsh SB, Waters A, Wilson P, Wong E, Taylor CM, Nitsch D, Saleem M, Bockenhauer D, Bramham K, Gale DPRaDaR consortium. Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort. Lancet. 2024 Mar 30;403(10433):1279-1289. doi: 10.1016/S0140-6736(23)02843-X. Epub 2024 Mar 13. PMID: 38492578.
- Moochhala SH, Worcester EM, Primary hyperoxaluria: the adult nephrologist's point of view, Clinical Kidney Journal, Volume 15, Issue Supplement_1, May 2022, Pages i29–i32, https://doi.org/10.1093/ckj/sfac068• Garrelfs S, Frishberg Y, Hulton S, Koren M, O’Riordan W, Cochoat P, Deschenes G, Shasha-Lavsky H, Saland J, van’t Hoff W, Fuster D, Magen D, Moochhala SH et al. Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. N Engl J Med 2021384:1216-1226. DOI: 10.1056/NEJMoa2021712
- Moochhala S, Unwin R. Electrolytes and acid–base: common fluid and electrolyte disorders. Medicine (Elsevier) July 2015, Volume 43, Issue 7, Pages 374–380.
Reviews
Major insurers served
If your insurer is not listed, please contact us to confirm your coverage. Please note this does not guarantee coverage or fee assurance. Patients should confirm with their insurer to ensure coverage, check if the doctor is fee-assured, or verify if their policy includes the doctor in question.